Examples of using Immunogenicity data in English and their translations into Portuguese
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
Clinical studies with Prevenar 13 currently provide immunogenicity data in adults aged 18 years
In addition to the immunogenicity data generated in the past 5 years from clinical trials with the PROCOMVAX data,
In addition to the immunogenicity data generated in the past 5 years from clinical trials with the HBVAXPRO
were observed in at least 64% of subjects at 1 week post vaccination see section 5.1 for immunogenicity data per individual serogroups.
Immunogenicity data.
Immunogenicity data in preterm infants.
Safety and immunogenicity data in healthy adults, including older people.
Safety and immunogenicity data in special risk groups immunocompromised
The dose recommendations take into account the safety and immunogenicity data from clinical studies in healthy subjects.
Safety and immunogenicity data are not yet available in children above 5 years of age.
Safety and immunogenicity data in healthy children and adolescents aged from
Immunogenicity data obtained at three weeks after administration of Humenza in clinical studies suggest that a single dose may be sufficient.
There are very limited safety and immunogenicity data available from clinical studies with HUMENZA in adults aged over 60 years of age.
Safety and immunogenicity data obtained three weeks after administration of two doses of Celvapan(H1N1)v to healthy children aged 6 months to 17 years.
available safety and immunogenicity data from both parts of the ongoing study.
Safety and immunogenicity data are available for a limited number of individuals with sickle cell disease,
This indication is based on immunogenicity data from subjects from the age of 6 months onwards following administration of two doses of vaccine prepared with H5N1 subtype strains see section 5.1.
The VWP considered the new submitted data along with the already submitted data and agreed that the safety and immunogenicity data are adequate
Immunogenicity data from three long-term clinical studies indicate that approximately one third of patients develop antibodies, as determined by
This indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared with H5N1 subtype strains see section 5.1.
